Chiemi Tsumagari-Mishima

Kita, 3319530, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Cryo-EM elucidates the interaction mechanism of ozoralizumab, a humanized anti-TNFα NANOBODY® compound.

Cryo-EM elucidates the interaction mechanism of ozoralizumab, a humanized anti-TNFα NANOBODY® compound.

Journal: Biochemical and biophysical research communications

Published: March 03, 2026

Structural insights into the binding mode of the hypnotic drug vornorexant to orexin receptors.

Structural insights into the binding mode of the hypnotic drug vornorexant to orexin receptors.

Journal: Acta crystallographica. Section F, Structural biology communications

Published: December 14, 2025

Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.

Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.

Journal: Biochemical and biophysical research communications

Published: July 02, 2024

RhoG facilitates a conformational transition in the guanine nucleotide exchange factor complex DOCK5/ELMO1 to an open state.

RhoG facilitates a conformational transition in the guanine nucleotide exchange factor complex DOCK5/ELMO1 to an open state.

Journal: The Journal of biological chemistry

Published: December 28, 2023

Discovery of novel indole derivatives as potent and selective inhibitors of proMMP-9 activation.

Discovery of novel indole derivatives as potent and selective inhibitors of proMMP-9 activation.

Journal: Bioorganic & medicinal chemistry letters

Published: August 24, 2023

Structural basis for the dual GTPase specificity of the DOCK10 guanine nucleotide exchange factor.

Structural basis for the dual GTPase specificity of the DOCK10 guanine nucleotide exchange factor.

Journal: Biochemical and biophysical research communications

Published: February 07, 2023

Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.

Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.

Journal: Frontiers in immunology

Published: January 23, 2023

Targeting Ras-binding domain of ELMO1 by computational nanobody design.

Targeting Ras-binding domain of ELMO1 by computational nanobody design.

Journal: Communications biology

Published: August 05, 2022

Crystal structure of human acetylcholinesterase in complex with tacrine: Implications for drug discovery.

Crystal structure of human acetylcholinesterase in complex with tacrine: Implications for drug discovery.

Journal: International journal of biological macromolecules

Published: December 20, 2021

Cryo-EM structure of the human ELMO1-DOCK5-Rac1 complex.

Cryo-EM structure of the human ELMO1-DOCK5-Rac1 complex.

Journal: Science advances

Published: December 28, 2020

Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.

Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.

Journal: Bioorganic & medicinal chemistry letters

Published: November 27, 2020

Reduced efficacy of a Src kinase inhibitor in crowded protein solution.

Reduced efficacy of a Src kinase inhibitor in crowded protein solution.

Journal: Nature communications

Published: September 04, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026